Skip to main content
Brain Communications logoLink to Brain Communications
. 2023 Oct 25;5(6):fcad291. doi: 10.1093/braincomms/fcad291

Reduced evoked cortical beta and gamma activity and neuronal synchronization in succinic semialdehyde dehydrogenase deficiency, a disorder of γ-aminobutyric acid metabolism

Christos Papadelis 1,2,3,, Georgios Ntolkeras 4,5, Itay Tokatly Latzer 6,7, Melissa L DiBacco 8, Onur Afacan 9, Simon Warfield 10, Xutong Shi 11, Jean-Baptiste Roullet 12, K Michael Gibson 13; SSADH Deficiency Investigators Consortium , Phillip L Pearl 14
PMCID: PMC10636566  PMID: 37953848

Abstract

Succinic semialdehyde dehydrogenase deficiency is a rare autosomal recessively inherited metabolic disorder of γ-aminobutyric acid catabolism manifested by intellectual disability, expressive aphasia, movement disorders, psychiatric ailments and epilepsy. Subjects with succinic semialdehyde dehydrogenase deficiency are characterized by elevated γ-aminobutyric acid and related metabolites, such as γ-guanidinobutyric acid, and an age-dependent downregulation of cerebral γ-aminobutyric acid receptors. These findings indicate impaired γ-aminobutyric acid and γ-aminobutyric acid sub-type A (GABAA) receptor signalling as major factors underlying the pathophysiology of this neurometabolic disorder. We studied the cortical oscillation patterns and their relationship with γ-aminobutyric acid metabolism in 18 children affected by this condition and 10 healthy controls. Using high-density EEG, we recorded somatosensory cortical responses and resting-state activity. Using electrical source imaging, we estimated the relative power changes (compared with baseline) in both stimulus-evoked and stimulus-induced responses for physiologically relevant frequency bands and resting-state power. Stimulus-evoked oscillations are phase locked to the stimulus, whereas induced oscillations are not. Power changes for both evoked and induced responses as well as resting-state power were correlated with plasma γ-aminobutyric acid and γ-guanidinobutyric acid concentrations and with cortical γ-aminobutyric acid measured by proton magnetic resonance spectroscopy. Plasma γ-aminobutyric acid, γ-guanidinobutyric acid and cortical γ-aminobutyric acid were higher in patients than in controls (P < 0.001 for both). Beta and gamma relative power were suppressed for evoked responses in patients versus controls (P < 0.01). No group differences were observed for induced activity (P > 0.05). The mean gamma frequency of evoked responses was lower in patients versus controls (P = 0.002). Resting-state activity was suppressed in patients for theta (P = 0.011) and gamma (P < 0.001) bands. Evoked power changes were inversely correlated with plasma γ-aminobutyric acid and with γ-guanidinobutyric acid for beta (P < 0.001) and gamma (P < 0.001) bands. Similar relationships were observed between the evoked power changes and cortical γ-aminobutyric acid for all tested areas in the beta band (P < 0.001) and for the posterior cingulate gyrus in the gamma band (P < 0.001). We also observed a negative correlation between resting-state activity and plasma γ-aminobutyric acid and γ-guanidinobutyric acid for theta (P < 0.001; P = 0.003), alpha (P = 0.003; P = 0.02) and gamma (P = 0.02; P = 0.01) bands. Our findings indicate that increased γ-aminobutyric acid concentration is associated with reduced sensory-evoked beta and gamma activity and impaired neuronal synchronization in patients with succinic semialdehyde dehydrogenase deficiency. This further elucidates the pathophysiology of this neurometabolic disorder and serves as a potential biomarker for therapeutic trials.

Keywords: epilepsy, high-density EEG (HD-EEG), inherited metabolic disorders, proton magnetic resonance spectroscopy (1H-MRS)


Papadelis et al. report abnormal electrophysiology (i.e. reduced evoked beta and gamma cortical activity) in individuals with succinic semialdehyde dehydrogenase deficiency, a disorder of γ-aminobutyric acid (GABA) degradation. These findings possibly represent elevated brain GABA’s negative effects on rhythmic synchronization and provide the grounds for the development of non-invasive biomarkers of GABA.

Graphical Abstract

Graphical abstract.

Graphical abstract

Introduction

Succinic semialdehyde dehydrogenase deficiency (SSADHD) is an ultra-rare autosomal recessively inherited disorder of γ-aminobutyric acid (GABA) degradation caused by inactivating mutations of the ALDH5A1 gene.1-4 Patients with SSADHD have profound neurological and psychiatric morbidity, including seizures, developmental disability, intellectual deficiency, language impairment and movement disorders.1,5-11 Lifespan does not appear to be affected, although there are reports of sudden unexplained death of epilepsy in SSADHD adults.12,13 Approximately 300 patients have been identified worldwide,1,14 but the true prevalence is likely higher considering the non-specific neurological phenotype and potential for under-diagnosis.

The biochemical hallmark of SSADHD is elevation of GABA, γ-hydroxybutyric acid and GABA-derived metabolites in physiologic fluids.15,16 Post-mortem tissue analyses in a patient with SSADHD recently reported elevations in concentrations of γ-guanidinobutyric acid (GGB).17 Imaging studies with flumazenil positron emission tomography showed decreased γ-aminobutyric acid sub-type A (GABAA) receptor binding, suggesting downregulation of GABAA receptors secondary to chronically elevated cortical levels of endogenous GABA.18 Cortical levels of the excitatory neurotransmitter glutamate are variable, but there is strong evidence of pronounced deficiency in brain glutamine, the metabolic precursor of glutamate and an essential component of the astrocyte-neuron GABA/glutamate recycling pathway.19-21 Together, these findings point to a significant impairment of central neurotransmission in SSADHD, with excessive GABA, decreased GABAA receptor activity and impaired GABA-glutamate recycling. These metabolic and signalling abnormalities are likely underlying the neurological and psychiatric manifestations of SSADHD. Yet, to date, this hypothesis lacks experimental confirmation.

Proton magnetic resonance spectroscopy (1H-MRS) enables in vivo non-invasive measurement of cortical glutamate and GABA. In healthy adults, 1H-MRS of GABA has been used to show functional regionally specific correlations between the levels of GABA in the brain and behaviour, such as tactile frequency discrimination22 and learning.23 Abnormal levels of GABA measured with 1H-MRS have been reported in several neurodevelopmental, psychiatric and neurological disorders.24 Recent animal25,26 and non-invasive human studies27,28 have also related in vivo cortical GABA measures with frequency-specific cortical oscillations. Previous magnetoencephalography (MEG) studies in healthy adults have demonstrated associations between gamma activity (∼40 Hz) during a visual stimulation task and 1H-MRS–derived cortical GABA concentrations29 and post-movement beta activity (from ∼15 to 30 Hz) during a finger motor task as well as GABA to N-acetyl-aspartate (NAA) ratio.30 A multi-modal MEG and flumazenil positron emission tomography study showed that GABAA receptor densities are positively correlated with frequency and negatively correlated with the amplitude of visually induced gamma oscillations in the primary visual cortex of healthy adults.31 Yet, there is still a lack of evidence linking the in vivo cortical GABA and cortical electrophysiological measures with the in vitro GABA plasma levels in healthy individuals as well as patients with a GABAergic disorder.

This study evaluated the neurophysiological effect of GABA on neuronal synchronization in subjects with SSADHD. To this end, we investigated the relationship between the amplitude and frequency of in vivo somatosensory evoked and induced cortical responses and resting-state brain activity, in vivo cortical GABA concentrations measured through 1H-MRS and in vitro plasma GABA and GGB concentrations in subjects with SSADHD versus healthy controls. We hypothesized that plasma GABA and GGB levels and resting-state 1H-MRS–derived cortical GABA concentrations will correlate negatively to somatosensory evoked and induced cortical response amplitude and power of beta and gamma frequency bands.

Material and methods

Participant recruitment

We recruited 18 patients with SSADHD [age: 2–39 years; median: 7 years (inter-quartile range: 4–12.5); 8 females] from the ongoing SSADHD Natural History Study led by Boston Children’s Hospital. The study received ethical approval from Boston Children’s Hospital Institutional Review Board (IRB-P00029917). All the enrolled patients had genetically confirmed SSADHD. We also recruited 10 neurotypical controls from the community, who did not differ in age range and sex distribution [age: 6–34 years; median: 14.3 (inter-quartile range: 10.6–22.5); five females]. Recruitment of the study group was unbiased, as subjects with all degrees of disease severity participated. The clinical severity scores of our study participants, as assessed by a validated SSADHD-specific severity scoring system,32 are detailed in Supplemental Table 1. This severity scoring system ranges from 5 (severe) to 25 (mild).

Plasma γ-aminobutyric acid and γ-guanidinobutyric acid

Plasma specimens were collected at Boston Children’s Hospital facilities by a registered phlebotomist according to the hospital’s specimen collection procedures.33 The specimens were placed in a lithium heparin tube, separated from cells after collection and frozen below −20°C. GABA concentrations were measured by ELISA using a commercially available kit (GABA ELISA kit, LDN, Nordhorn, Germany). Measurements of GGB concentrations were performed using stable isotope dilution gas chromatography-mass spectrometry as previously described.34

Resting-state brain activity and somatosensory cortical responses

We recorded resting-state brain activity and somatosensory-evoked responses to pneumatic stimuli of upper extremities from all participants with a sampling rate of 1 KHz using a 64-channel high-density EEG (HD-EEG) system (eegoTMmylab, ANT Neuro, Netherlands; Fig. 1A). We selected the use of pneumatic stimulation to elicit cortical responses (instead of far-field somatosensory responses with transcutaneous electrical stimulation) because is more suitable for children, particularly those with developmental delays. We initially placed the HD-EEG cap on the participant’s head and ensured that resistances were <10 KOhms for all electrodes. Then, we recorded resting-state data for 5 min, during which the participants had their eyes open, fixating on a cartoon figure displayed on a screen in front of them. Eyes fixation on a visual target is a well-established experimental paradigm used from several researchers who examine resting-state brain activity.35,36 This technique is used to minimize the contamination of EEG signals from biological artefacts generated by eye movements, eye blinking and saccades.

Figure 1.

Figure 1

Somatosensory cortical responses. (A) HD-EEG cap (64 channels) on the head of a patient with SSADHD (patient #1); (inlet panel) pneumatic stimulators attached to the distal, volar parts of the patient’s four digits (i.e. thumb, index, middle finger, and pinky). (B) Relative location of HD-EEG electrodes with respect to patient’s scalp and cortex (upper panel), and location of the virtual channel placed contralateral to the stimulation site’s primary somatosensory cortex (S1) (lower panel). (C) Averaged somatosensory-evoked cortical responses for all digits for this patient (upper panel) in μV and cortical responses (absolute values) at the virtual channel in contralateral S1.

Somatosensory-evoked responses were elicited by tactile stimulation of four digits (i.e. thumb, index finger, middle finger and pinky). In consequent recording sessions, we stimulated both hands by gently tapping the skin at the tip of the four digits. We delivered tactile stimuli through thin elastic membranes attached to the distal, volar parts of the four digits (inlet panel in Fig. 1A). The membranes were inflated with compressed air pulses through rigid plastic tubes using the Somatosensory Stimulus Generator (4D NeuroImaging Inc., San Diego, CA, USA). The compressed air pulses were released with an inter-stimulus interval of 1.5 ± 0.5 s following a pseudo-random order. The pressure of the tactile stimulator rose to 0.10 bar overpressure in 10 ms. The recordings lasted ∼15 min per hand; the total duration of the actual recording was ∼1 h (including resting state, somatosensory-evoked responses and breaks between runs). We stimulated each finger with at least 200 stimuli. Stimulations were delivered in consecutive short duration (∼1.5 min) runs with 20 stimuli per finger (80 stimuli in total). If excessive movements were observed, the session was repeated. Electrocardiography data were simultaneously collected with a sampling rate of 1 KHz through two leads positioned on the sternum and the fifth intercostal space on the left side of the body.

MRI and co-registration with EEG

We acquired MRI with magnetization-prepared rapid acquisition gradient-echo sequences (MPRAGE; Echo Time = 1.74 ms, Repetition Time = 2, 520 ms, voxel size = 1 × 1 × 1 mm) using a 3 T scanner (Skyra, Siemens AG, Germany). We performed co-registration between the participants’ head shape (extracted from the MRI) and the HD-EEG sensor locations using ‘Brainstorm’ (Fig. 1B).37 We defined the relative location of HD-EEG electrodes with respect to the patients’ head anatomy with the FASTRACK tracking system (Polhemus, Colchester, VT, USA). Prior to the experiment, we asked the participants to sit on a special chair where the FASTTRACK transmitter was attached. We placed the FASTRACK receiver on the participants’ heads using a headband. With the FASTRACK stylus, we digitized three anatomical landmarks on the participants’ heads (i.e. nasion, left pre-auricular point and right pre-auricular point) as well as the HD-EEG electrode locations. MRI data for one patient with SSADHD and two healthy controls were unavailable. For these patients, we used an age-appropriate MRI template for further analysis.38

High-density EEG data analysis

We analysed the HD-EEG data using Brainstorm.37 We initially inspected the data to remove myogenic artefacts and then performed independent component analysis on HD-EEG and electrocardiography data to remove biological artefacts, e.g. pulse artefacts.39,40 We then removed the DC offset and filtered the data with a fourth-order band-pass infinitive impulse response Butterworth filter (1–100 Hz) and the 60 Hz notch filter.

For the resting-state data, we estimated the power spectrum density (Welch) of the HD-EEG signal across all EEG frequency bands (delta: 1–4 Hz; theta: 4–8 Hz; alpha: 8–12 Hz; beta: 12–30 Hz; and gamma: 30–100 Hz). For the somatosensory evoked and induced cortical oscillations, we segmented each dataset into trials from −100 to 500 ms relative to the stimulus onset. We tested whether the number of useful trials differed between stimulation sites or groups; we found no significant differences (P > 0.05).

Electric source imaging

We performed electric source imaging on the averaged data of each participant using the standardized Low-Resolution Electromagnetic Tomography, which estimates the 3D distribution of electric neuronal activity in the brain.41 For the standardized Low-Resolution Electromagnetic Tomography estimation, we used the default parameters in ‘Brainstorm’. We averaged the source imaging maps across runs for each participant and hand site. We built realistic head models using the boundary element model based on each participant’s MRI scan to estimate the forward model.42 The models were generated with the OpenMEEG software43 and consisted of four surface layers (i.e. brain, inner skull, outer skull and head surface). The standardized Low-Resolution Electromagnetic Tomography solutions44 were estimated at the cortical surface (∼15 000 sources) reconstructed in ‘Brainstorm’ using Statistical Parametric Mapping functions.

Time–frequency analysis at virtual channels

We identified the peak of the first cortical responses after the stimulus onset for all participants (upper panel in Fig. 1C). We then generated virtual channels at the locations where maximum cortical activity was observed (lower panel in Fig. 1C). The latency and amplitude at the first peak of cortical response after stimulus onset were calculated for each virtual channel. We performed a time–frequency analysis of the electric brain activity at the virtual channels using a complex Morlet wavelet. To estimate evoked responses, we applied the Morlet wavelets (five circles width per wavelet at centre frequencies between 1 and 100 Hz in 1 Hz steps) to the averaged source waveforms of each run of each digit for each participant. We then corrected the time–frequency representations with respect to the baseline activity from −100 to 0 ms to estimate relative power changes.45 To estimate induced responses, we applied the Morlet wavelets (using the same parameters as for the evoked responses) to the source waveforms from the individual trials of each digit for each participant. We then corrected the time–frequency representations with respect to the baseline activity for each trial and averaged them.

Cortical γ-aminobutyric acid derived by proton magnetic resonance spectroscopy

We used a MEGA PRESS sequence46,47 to measure GABA, acquired in a single voxel with size 27 cc (30 × 30 × 30 mm). We collected data from three brain regions: basal ganglia, posterior cingulate gyrus and occipital lobe. The basal ganglia were sampled as it is the area with the most consistent MRI abnormalities in SSADHD.46 The posterior cingulate gyrus and occipital lobe were sampled for control, since these areas were demonstrated to be applicable to GABA measurement.48-50 We processed the spectroscopy data using the LCModel software to estimate the concentrations of GABA and NAA. To remove potential bias due to neuronal loss, we measured the ratio of GABA/NAA.

Statistical analysis

The various diagnostic tests were performed and interpreted by blinded observers working in separate research groups. Analysis of HD-EEG data was performed by C.P. and G.N., analysis of 1H-MRS data was performed by O.A. and S.W. and analysis of plasma GABA and GGB was performed by X.S. and K.M.G. We performed statistical analysis of the resting-state and the somatosensory evoked and induced cortical oscillations data with SPSS 23.0 (SPSS Inc., Chicago, IL, USA). For the time–frequency analysis, we analysed the time–frequency representations between subjects (healthy controls versus patients with SSADHD). All statistical tests were employed using Monte Carlo permutation tests (5000 permutations). The arising multiple comparison problem was corrected with cluster-based statistical analysis.51 For each participant, we extracted the mean frequency of relative responses within the time windows and frequency bands where statistically significant differences were observed between the two groups. The beta and gamma frequencies and the SSADHD clinical severity score, which were distributed parametrically, were correlated using the Pearson correlation coefficient. Linear and non-linear curve fitting of the relationships between variables (i.e. relative power changes, plasma GABA and GGB concentrations, cortical GABA-derived by 1H-MRS and age) were performed. Best fits (highest r values) were selected. Linear regression analyses were then performed with Statgraphics Centurion 18 (Statgraphics Technologies, Inc., The Plains, VA, USA) using transformed values of X {e.g. [Power] = f[SQRT(GABA)] or [Power] = f[LOG(GBA)]} to obtain regression coefficients r and statistical significance, P values.

Results

Cohort

None of the study participants was diagnosed with neurological conditions that may confound the somatosensory evoked responses, such as a cerebrovascular accident or brain tumour. Notably, 8/18 patients were diagnosed with epilepsy, from whom 5 had a rare seizure frequency (≤1/year) and 1 had focal seizures per semiology but without a seizure focus per neuroimaging. Moreover, none of those presenting with seizures experienced sensory epileptic auras or seizures with sensory features that may affect the somatosensory-evoked responses. However, four subjects with epilepsy did take anti-seizure medications (Supplemental Table 1) that may modulate the resting-state EEG power spectrum52 and somatosensory-evoked potentials.53 None of the study’s participants sustained peripheral nerve disorders and myelopathy; these manifestations are not known to be part of the clinical phenotype of SSADHD.

Plasma γ-aminobutyric acid and γ-guanidinobutyric acid

We collected plasma specimens from 16 subjects with SSADHD (mean age ± SE: 11.18 ± 2.64) and 8 controls (mean age ± SE: 18.14 ± 2.91). The two groups had no significant age differences (P = 0.09). Plasma GABA was higher in patients with SSADHD than in healthy controls (mean ± SE: 3.29 ± 0.25 μM versus 1.44 ± 0.04 μM in SSADHD and healthy controls, respectively; P < 0.001). Plasma GGB was also higher in subjects with SSADHD (0.09 ± 0.01 μM) than in healthy controls (0.03 ± 0.00, P < 0.001).

Evoked and induced responses in contralateral primary somatosensory cortex (S1)

Somatosensory stimulation of the upper extremities resulted in a prominent cortical response at the virtual channel located within the S1 contralateral to stimulation for all healthy controls and patients with SSADHD (Fig. 1C). Statistical analysis of evoked responses between the different groups showed suppressed relative power in subjects with SSADHD compared with healthy controls in beta and gamma frequency bands (beta: 307.25% ± 50.81 versus 1008.18% ± 74.18; P < 0.001; gamma: 4.98% ± 21.7 versus 388.88% ± 96.67; P < 0.001; Fig. 2). The suppression of relative power was observed from 0 till ∼130 ms after the stimulus onset between ∼15 and ∼30 Hz for the beta band (Fig. 2). The suppression for the gamma band was observed later from ∼85 until ∼130 ms after stimulus onset between ∼55 and ∼65 Hz (Fig. 2). No differences of relative power between the two groups were observed for induced activity (P > 0.05). The mean frequency of relative power changes within the gamma band was lower in patients with SSADHD versus healthy controls (38.22 versus 42.59 Hz; P = 0.002). We also observed a moderate positive correlation between the mean frequency of relative power changes within the beta band with age (r = 0.527; P < 0.008). No frequency differences between the two groups were observed for induced activity (P > 0.05).

Figure 2.

Figure 2

Time–frequency analysis for evoked cortical responses in contralateral S1 for healthy controls (n = 10) and patients with SSADHD (n = 18). Grant average of relative power changes with respect to baseline (in %) at the virtual channel contralateral to the S1 for healthy children (upper panel) and patients with SSADHD (lower panel). Highlighted areas with an asterisk (*) indicate statistically significant differences between the two groups [Monte Carlo permutation tests (5000 permutations); corrected for multiple comparisons; P < 0.01]. RPC (%), relative power change.

Cortical γ-aminobutyric acid/N-acetyl-aspartate derived by proton magnetic resonance spectroscopy

Cortical GABA/NAA ratios were higher in subjects with SSADHD than in healthy controls for all the examined brain regions. In basal ganglia, GABA/NAA ratios were 0.132 ± 0.011 for healthy controls (mean ± SE; n = 9) and 0.223 ± 0.019 for children with SSADHD (n = 8, P < 0.001). In the posterior cingulate gyrus, these ratios averaged 0.088 ± 0.004 in healthy controls (n = 9) and 0.228 ± 0.009 in patients with SSADHD (n = 11, P < 0.001), whereas in the occipital cortex, they were 0.035 ± 0.010 and 0.156 ± 0.012 for healthy controls and SSADHD, respectively (n = 8 per group, P < 0.001).

Relationships between relative power, plasma γ-aminobutyric acid and γ-guanidinobutyric acid, and cortical γ-aminobutyric acid/N-acetyl-aspartate

When SSADHD and healthy control data were analysed together, we observed inverse relationships between the relative power of evoked cortical responses in the beta band and both the GABA (r = −0.75; P = 0.0001) and GGB (r = −0.69; P = 0.0002) plasma concentrations (Fig. 3). An inverse relationship was also noted between the relative power of evoked cortical responses in the gamma band and the concentrations of plasma GABA (r = −0.61; P = 0.002) and GGB (r = −0.55; P = 0.007; Fig. 4).

Figure 3.

Figure 3

Correlation of relative power changes in beta-band with plasma GABA and GGB. Correlation of relative power changes in beta band with Plasma GABA (left; P < 0.0001, r = −0.75) and GGB (right; P < 0.0001, r = −0.69). Relative power change, change in the power of the EEG signal (%) during the active period (after pneumatic stimulation) compared with the baseline period (before stimulation). Dotted lines = best fit: SQRT(X) (left), LOG(X) (right). Regression analysis was performed to obtain regression coefficients and P-values.

Figure 4.

Figure 4

Correlation of relative power changes in gamma-band with plasma GABA and GGB. Correlation of relative power changes in gamma band with plasma GABA (left; P < 0.0026, r = −0.61) and GGB (right; P < 0.0074, r = −0.55). Relative power change, change in the power of the EEG signal (%) during the active period (after pneumatic stimulation) compared with the baseline period (before stimulation). Dotted lines = best fit: SQRT(X) (left), LOG(X) (right). Regression analysis was performed to obtain regression coefficients and P-values.

Similar relationships were observed between the relative power of evoked cortical responses in the beta band and GABA/NAA ratios measured in the basal ganglion (r = −0.70; P < 0.001) and between the relative power of evoked cortical responses in the gamma band and the GABA/NAA ratios measured in the basal ganglion (r = −0.79; P < 0.002) and the posterior cingulate gyrus (r = −0.85; P < 0.004; Fig. 5). Notably, the SSADHD clinical severity scores (Supplemental Table 1) were not significantly correlated to the beta (r = 0.227, P = 0.36) or gamma (r = 0.082, P = 0.74) bands.

Figure 5.

Figure 5

Relationship between relative power changes and brain GABA/NAA. Relationship between the relative power changes (%) and 1H-MRS–GABA/NAA ratios in patients with SSADHD (○) and controls (●) for beta band (A: basal ganglion) and gamma band (B: basal ganglion; C: posterior cingulate gyrus; D: occipital cortex). Dotted lines = best fit: linear (A, D), reciprocal (X) (B, C). Regression analysis was performed to obtain regression coefficients and P-values.

Cortical resting-state activity

Resting-state cortical activity within the contralateral S1 was suppressed for subjects with SSADHD compared with healthy controls for the theta (mean age ± SE: 63.76 μV2/Hz ± 7.44 versus 95.75 μV2/Hz ± 7.04; P = 0.01) and gamma frequency bands (mean age ± SE: 170.47 μV2/Hz ± 65.60 versus 780.91 μV2/Hz ± 176.49; P < 0.001). No differences between the two groups were observed for the other frequency bands (i.e. delta, alpha and beta; Table 1).

Table 1.

High-density EEG resting-state cortical activity

Delta Theta Alpha Beta Gamma
SSADHD
 n 18 18 17 18 18
Mean 15.64 63.76 187.55 451.93 170.47
SEM 2.43 7.44 46.01 122.91 65.60
Outliers
Controls
 n 9 9 10 10 10
Mean 18.49 95.75 250.91 502.96 780.91
SEM 1.97 7.04 68.83 64.62 176.49
Outliers 2 1
 t-test (P-value) 0.4522 0.0113* 0.4346 0.7702 0.0006*

n, number of participants in the group; SEM, standard error of measurement. *Statistically significant P-values <0.05.

Correlation of resting-state cortical activity with plasma γ-aminobutyric acid and γ-guanidinobutyric acid

We observed a significant inverse correlation between resting-state cortical activity and plasma GABA and GGB values for the theta (GABA: r = −0.0651, P < 0.001; GGB: r = −0.5718; P = 0.003), alpha (GABA: r = −0.5818, P = 0.003; GGB: r = −0.4806; P = 0.02) and gamma (GABA: r = −0.4586, P = 0.02; GGB: r = −0.4842; P = 0.01) frequency bands.

We also observed a positive correlation of the resting-state cortical activity with the age of all participants for the theta (r = 0.5967, P = 0.002) and alpha bands (r = 0.5122, P = 0.01; Table 2).

Table 2.

Correlation of resting-state high-density EEG cortical activity with blood GABA, blood GGB, and age

Delta Theta Alpha Beta Gamma
GABA
 Type Linear Linear Logarithmic X
P-value N.S. 0.0005 0.0036 N.S. 0.0242
r N.S. −0.0651 −0.5818 N.S. −0.4586
 Equation Theta LR = 121.966–18.3234 × blood GABA Alpha LR = 479.462–96.1928 × blood GABA Gamma LR = 829.512–488.724 × ln(blood GABA)
GGB
 Type Reciprocal X Linear Logarithmic X
P-value N.S. 0.0035 0.0203 N.S. 0.0142
r N.S. −0.5718 −0.4806 N.S. −0.4842
 Equation Theta LR = 54.1237 + 0.757898/blood GBA Alpha LR = 391.33–2589.4 × blood GBA Gamma LR = −568.433−339.844 × ln(blood GBA)
Age
 Type Reciprocal X Logarithmic X
P-value N.S. 0.0021 0.0125 N.S. N.S.
r N.S. 0.5967 0.5122 N.S. N.S.
 Equation Theta LR = 93.4471–142.869/age Alpha LR = −52.9342 + 120.79 × ln(age)

Discussion

Using the combination of HD-EEG–derived somatosensory-evoked cortical responses, electrical source imaging and cortical and plasma GABA measurements, this study’s findings determined that compared with controls, subjects with SSADHD are characterized by: (i) suppression of the relative power in somatosensory-evoked beta and gamma bands; (ii) a lower frequency of gamma activity; (iii) an inverse correlation of plasma GABA and GGB levels, as well as in vivo cortical GABA in all regions studied (i.e. basal ganglia, posterior cingulate gyrus and occipital cortex), with evoked beta and gamma activity in the posterior cingulate cortex; and (iv) decreased resting-state activity in the theta and gamma bands and an inverse correlation among cortical theta, alpha and gamma resting-state activity and plasma GABA and GGB levels.

To our knowledge, this study represents the first report of abnormal evoked electrophysiology in individuals with abnormally increased endogenous GABA levels. It partly elucidates the negative influence increased GABA may have on active neural networks’ rhythmic synchronization and accordingly sensory processing. Our findings provide a neurophysiologic demonstration of the downregulation of GABA receptor activity, as supported by flumazenil ligand radioisotope PET scanning, and support a basic physiological role for GABA as underlying cortical gamma activity. These findings further indicate the potential development of novel non-invasive biomarkers of GABAergic dysfunction. Such biomarkers may augment the early diagnosis of neurometabolic disorders as well as the development and monitoring of future disease-modifying interventions.

GABA, the main inhibitory neurotransmitter in the central nervous system, has been suggested to play a role in the pathophysiological processes of several neurodevelopmental disorders.54-62 In addition, an age-related reduction in otherwise elevated concentrations of GABA has been associated with motor cortex dysfunction as well as epileptogenesis and autism spectrum disorders in SSADHD.63-65 Plasma GABA concentrations likely reflect its synthesis, accumulation and release from tissues, as well as hepatic and peripheral tissue clearance. Changes in the gut microbiota of patients may also contribute to the pathophysiological levels of elevated GABA in patients with SSADHD.66,67 Yet, plasma GABA may not be directly related to tissue concentrations in the central nervous system. Thus, other indirect measures of cortical GABA are required. Recent progress in the non-invasive evaluation of GABA levels in the human brain has been achieved by means of 1H-MRS. Here, we observed a cortical GABA increase in subjects with SSADHD for all brain regions quantified compared with healthy controls. This was coupled with somatosensory stimulation of the upper extremities that induced a prominent cortical response in the beta and gamma frequency bands. A relative power change, namely event-related synchronization,47 within these bands, was expected since it aligns with previous findings by our group and others using the same or similar experimental paradigms.68-72 Both beta and gamma frequencies play a critical role in somatosensory processing; beta activities likely relate to the independent representation of sensory input, while gamma oscillations likely relate to the binding of sensory information for higher order processing.71 Here, we observed a suppression of relative power change in both beta and gamma frequency bands for subjects with SSADHD compared with healthy controls. A similar suppression of gamma-evoked activity (but in response to auditory stimuli) has been reported recently in a cohort of children with Dravet syndrome,73 a neurodevelopmental disease involving dysfunction of GABAergic mechanisms. Other studies have shown altered gamma oscillations in disorders with impaired balance between excitatory and inhibitory neurotransmission, including autism spectrum disorders,74 depression,75 cognitive disorders76 and several other neuropsychiatric disorders.77

Suppressed evoked activity may be explained by: (i) a decrease in the amplitude of oscillatory activities elicited by each individual stimulus; (ii) a decrease in the number of neurons corresponding to the stimulus, and/or (iii) a deficiency in the synchronization mechanisms needed to elicit a coherent response.78 The increase of GABA characteristic of SSADHD presumably alters the ability of interneurons to elicit an appropriate response stimulus, causing desynchronization of the evoked responses.

A MEG study in healthy adults showed that the peak frequency of network gamma oscillations induced by visual stimulation was positively correlated with the concentration of GABA measured through 1H-MRS.29 In a later study, the same research group found no alteration of gamma frequency in response to direct manipulation of GABA through administration of tiagabine, which increases endogenous GABA levels, for either induced or evoked responses.79 Here, we found that the frequency of gamma-evoked responses was lower in patients with SSADHD versus healthy controls. Potential reasons for these apparently contradictory findings are the different experimental paradigms used in these studies (previous studies used visual stimulation versus somatosensory stimuli here) and, more importantly, the chronic nature of endogenous impairment of GABA catabolism in SSADHD. Our findings align with a realistic cortical network modelling study in which interneurons and excitatory pyramidal cells are interconnected in re-entrant loops.80 In this model, the dominant population response occurs in the gamma frequency band and depends strongly on the ratio between excitatory and inhibitory connections and their time constants. This model predicts that as inhibition increases, the dominant frequency will increase. Consistent with the compensatory downregulation of GABAergic activity in this developmental disorder, however, the actual mean frequency of gamma activity is demonstrated to be decreased.

Suppressed resting-state activity in the theta and gamma bands was observed in subjects with SSADHD compared with healthy controls. A negative correlation between the resting-state cortical activity and the plasma GABA and GGB was also seen for the theta, alpha and gamma frequency bands. Ongoing gamma band oscillations of the local field potential synchronize neuronal response onset latencies to sensory input.81 This synchronization of gamma band oscillations seems to play a critical role in conscious perception and sensory motor integration.82 Such dysfunction in the synchronization of oscillatory brain activity may explain the vast variety of heterogeneous cognitive impairments seen in SSADHD. Our finding that higher GABA levels (as in patients with SSADHD) are associated with greater suppression of theta frequency band appears to be consistent with the observation that GABA input reduces theta oscillations, and GABA blockade augments theta oscillations in animals.83,84 A pilot study in patients with schizophrenia, which investigated the relationship between frequency gating and GABA levels measured with 1H-MRS, showed similar findings of higher GABA levels with greater suppression of theta and theta-alpha gating.85 In line with our findings are also repetitive transcranial magnetic stimulation studies showing that non-invasive cortical stimulation in theta frequency leads to pronounced decrease in the excitability of cortical circuits.86

The most plausible mechanism for generating temporally organized electrocortical activity measured with scalp EEG is in reciprocally connected neuronal networks containing mixtures of inter-connected glutamatergic (excitatory) pyramidal and stellate cells, and GABAergic (inhibitory) interneurons.87,88 We may thus presume that alterations in cortical GABA will also alter the frequency and amplitude of neurophysiological (induced and evoked) responses to external sensory stimuli. This notion is supported by previous MEG studies involving visual and motor experimental paradigms in healthy adults. Muthukumaraswamy et al.29 have shown that the frequency of visual stimulus-induced network gamma oscillations in the primary visual cortex was positively correlated with the cortical GABA concentration measured with 1H-MRS. Using the same visual experiment, the same research group later reported no changes in the stimulus-induced amplitude during pharmacological manipulation of endogenous GABA in healthy adults, but a 45% suppression of evoked responses at ∼80 ms after the stimulus onset.79 A multi-modal MEG and flumazenil positron emission tomography study showed that GABAA receptor densities are correlated positively with the frequency and negatively with the amplitude of visually induced gamma oscillations in the primary visual cortex of healthy adults.31 Finally, another group of researchers showed a linear relation between motor-induced electrocortical activity in the beta and gamma frequency bands and the cortical GABA assessed through 1H-MRS.30

Here, we examined the relationship among electrocortical activity, cortical GABA levels assessed through 1H-MRS and plasma GABA in healthy controls and a cohort of patients with SSADHD. We observed a negative correlation of evoked activity in the beta and gamma frequency bands with plasma GABA and GGB. This observation is in line with previous MEG findings showing suppression of electrocortical activity at the early components of visually evoked fields after administration of the drug tiagabine in a set of healthy control participants.79 Tiagabine is an anticonvulsant that elevates the extracellular/synaptic concentration of GABA and therefore enhances the actions of endogenous GABA.89,90 Altogether, these findings demonstrate that early-evoked responses to external sensory inputs show greater sensitivity to increases in endogenous GABA compared with induced oscillations.

Despite its innovation, our study presents some limitations. The cortical level of GABA was assessed through 1H-MRS at large voxels centred at three different brain areas (i.e. basal ganglia, posterior cingulate gyrus and occipital cortex). These levels of GABA were correlated with induced and evoked changes of cortical activity elicited by somatosensory stimulation. Yet, none of the voxels, where cortical GABA level was assessed, were along the somatosensory pathway. Future studies should examine cortical responses from different neural systems (e.g. auditory, visual and somatosensory) and correlate them with the cortical GABA levels at locations that correspond to the anatomical pathways of these systems. To elicit cortical responses, we used a task that involves the presentation of a visual stimulus (i.e. cartoon). Since the same stimulus was used across all participants, the observed differences in cortical activity between the two groups were not affected by our paradigm. Yet, future studies should consider other resting-state conditions (i.e. eyes-open and eyes-closed without visual input), since different resting-state conditions produce different levels of cortical activity particularly in the alpha frequency band.91 Since our study focused on the somatosensory system, we restricted our resting-state EEG analysis to a virtual channel estimated in the contralateral S1. Future studies should examine resting-state EEG changes at the global level for both patients with SSADHD as well as other disorders of GABA.

Conclusions

We combined in vivo and in vitro measurements of GABA and GGB with event-related power changes utilizing HD-EEG recordings in response to tactile stimulation in a population of individuals with SSADHD, a neurodevelopmental disorder of impaired GABA metabolism. Our findings demonstrate that subjects with SSADHD, compared with healthy controls, showed decreased beta and gamma frequency band activity and decreased event-related synchronization. These findings possibly represent elevated brain GABA’s negative effects on rhythmic synchronization and cortical processing. By elucidating the GABAergic influences on normal neurophysiology, these findings may further provide the grounds on which non-invasive biomarkers could be developed for individuals with SSADHD and other developmental encephalopathies.

Supplementary Material

fcad291_Supplementary_Data

Acknowledgement

We thank the individuals with SSADHD and their families for their cooperation.

Appendix I

The SSADH Deficiency Investigators Consortium (SDIC): Phillip L. Pearl, Jean-Baptiste Roullet, K. Michael Gibson, Christos Papadelis, Thomas Opladen, Alexander Rotenberg, Kiran Maski, Melissa Tsuboyama, Simon Warfield, Onur Afacan, Edward Yang, Carolyn Hoffman, Kathrin Jeltsch, Jeffrey Krischer, M. Ángeles Garcıa Cazorla, and Erland Arning.

Contributor Information

Christos Papadelis, Jane and John Justin Institute for Mind Health, Cook Children’s Health Care System, Fort Worth, TX 76104, USA; School of Medicine, Texas Christian University, Fort Worth, TX 76129, USA; Department of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA.

Georgios Ntolkeras, Division of Newborn Medicine, Department of Medicine, Fetal-Neonatal Neuroimaging and Developmental Science Center, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA; Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.

Itay Tokatly Latzer, Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02129, USA; Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel.

Melissa L DiBacco, Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02129, USA.

Onur Afacan, Department of Radiology, Computational Radiology Laboratory, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02129, USA.

Simon Warfield, Department of Radiology, Computational Radiology Laboratory, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02129, USA.

Xutong Shi, Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA 99202, USA.

Jean-Baptiste Roullet, Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA 99202, USA.

K Michael Gibson, Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA 99202, USA.

Phillip L Pearl, Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02129, USA.

SSADH Deficiency Investigators Consortium:

Phillip L Pearl, Jean-Baptiste Roullet, K Michael Gibson, Christos Papadelis, Thomas Opladen, Alexander Rotenberg, Kiran Maski, Melissa Tsuboyama, Simon Warfield, Onur Afacan, Edward Yang, Carolyn Hoffman, Kathrin Jeltsch, Jeffrey Krischer, M Ángeles Garcıa Cazorla, and Erland Arning

Supplementary material

Supplementary material is available at Brain Communications online.

Funding

Funding provided by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, grant number: 5R01HD091142 supported the work presented in this manuscript. The Boston Children’s Hospital (BCH) Intellectual and Developmental Disabilities Research Center (BCH IDDRC, U54HD090255) also supported this study.

Competing interests

The authors report no competing interests.

Data availability

Anonymized data are available from the corresponding author upon request.

References

  • 1. Lapalme-Remis  S, Lewis  EC, De Meulemeester  C, et al.  Natural history of succinic semialdehyde dehydrogenase deficiency through adulthood. Neurology. 2015;85(10):861–865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Rodan  LH, Gibson  KM, Pearl  PL. Clinical use of CSF neurotransmitters. Pediatr Neurol. 2015;53:277–286. [DOI] [PubMed] [Google Scholar]
  • 3. Malaspina  P, Roullet  JB, Pearl  PL, Ainslie  GR, Vogel  KR, Gibson  KM. Succinic semialdehyde dehydrogenase deficiency (SSADHD): Pathophysiological complexity and multifactorial trait associations in a rare monogenic disorder of GABA metabolism. Neurochem Int. 2016;99:72–84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Attri  SV, Singhi  P, Wiwattanadittakul  N, et al.  Incidence and geographic distribution of succinic semialdehyde dehydrogenase (SSADH) deficiency. JIMD Rep. 2017;34:111–115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Gibson  KM, Gupta  M, Pearl  PL, et al.  Significant behavioral disturbances in succinic semialdehyde dehydrogenase (SSADH) deficiency (gamma-hydroxybutyric aciduria). Biol Psych. 2003;54:763–768. [DOI] [PubMed] [Google Scholar]
  • 6. Knerr  I, Gibson  KM, Jakobs  C, Pearl  PL. Neuropsychiatric morbidity in adolescent and adult succinic semialdehyde dehydrogenase deficiency patients. CNS Spectr. 2008;13:598–605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Knerr  I, Gibson  KM, Murdoch  G, et al.  Neuropathology in succinic semialdehyde dehydrogenase deficiency. Pediatr Neurol. 2010;42:255–258. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Vogel  KR, Pearl  PL, Theodore  WH, McCarter  RC, Jakobs  C, Gibson  KM. Thirty years beyond discovery–clinical trials in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism. J Inherit Metab Dis. 2013;36:401–410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Parviz  M, Vogel  K, Gibson  KM, Pearl  PL. Disorders of GABA metabolism: SSADH and GABA-transaminase deficiencies. J Pediatr Epilepsy. 2014;3(4):217–227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Pearl  PL, Schreiber  J, Theodore  WH, et al.  Taurine trial in succinic semialdehyde dehydrogenase deficiency and elevated CNS GABA. Neurology. 2014;82(11):940–944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Gogou  M, Spilioti  M, Tramma  D, Papadopoulou-Alataki  E, Evangeliou  A. Succinic semialdehyde dehydrogenase deficiency presenting as autism spectrum disorder. Indian J Pediatr. 2016;83:1036–1037. [DOI] [PubMed] [Google Scholar]
  • 12. Pearl  PL, Shukla  L, Theodore  WH, Jakobs  C, Gibson  KM. Epilepsy in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism. Brain Dev. 2011;33:796–805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Horino  A, Kawawaki  H, Fukuoka  M, et al.  A case of succinic semialdehyde dehydrogenase deficiency with status epilepticus and rapid regression. Brain Dev. 2016;38:866–870. [DOI] [PubMed] [Google Scholar]
  • 14. Pearl  PL, Novotny  EJ, Acosta  MT, Jakobs  C, Gibson  KM. Succinic semialdehyde dehydrogenase deficiency in children and adults. Ann Neurol. 2003;54(Suppl 6):S73–S80. [DOI] [PubMed] [Google Scholar]
  • 15. Snead  OC, Gibson  KM. Gamma-hydroxybutyric acid. N Engl J Med. 2005;352:2721–2732. [DOI] [PubMed] [Google Scholar]
  • 16. Maitre  M, Klein  C, Mensah-Nyagan  AG. Mechanisms for the specific properties of γ-hydroxybutyrate in brain. Med Res Rev. 2016;36(3):363–388. [DOI] [PubMed] [Google Scholar]
  • 17. Pearl  PL, Gibson  KM, Cortez  MA, et al.  Succinic semialdehyde dehydrogenase deficiency: Lessons from mice and men. J Inherit Metab Dis. 2009;32(3):343–352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Kirby  T, Walters  DC, Brown  M, et al.  Post-mortem tissue analyses in a patient with succinic semialdehyde dehydrogenase deficiency (SSADHD). I. Metabolomic outcomes. Metab Brain Dis. 2020;35(4):601–614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Westergaard  N, Sonnewald  U, Petersen  SB, Schousboe  A. Glutamate and glutamine metabolism in cultured GABAergic neurons studied by 13C NMR spectroscopy may indicate compartmentation and mitochondrial heterogeneity. Neurosci Lett. 1995;185(1):24–28. [DOI] [PubMed] [Google Scholar]
  • 20. Hertz  L. The glutamate-glutamine (GABA) cycle: Importance of late postnatal development and potential reciprocal interactions between biosynthesis and degradation. Front Endocrinol (Lausanne). 2013;4:59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Mazaud  D, Kottler  B, Gonçalves-Pimentel  C, et al.  Transcriptional regulation of the glutamate/GABA/glutamine cycle in adult glia controls motor activity and seizures in Drosophila. J Neurosci. 2019;39(27):5269–5283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Puts  NA, Edden  RA, Evans  CJ, McGlone  F, McGonigle  DJ. Regionally specific human GABA concentration correlates with tactile discrimination thresholds. J Neurosci. 2011;31(46):16556–16560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Floyer-Lea  A, Wylezinska  M, Kincses  T, Matthews  PM. Rapid modulation of GABA concentration in human sensorimotor cortex during motor learning. J Neurophysiol. 2006;95(3):1639–1644. [DOI] [PubMed] [Google Scholar]
  • 24. Puts  NA, Edden  RA. In vivo magnetic resonance spectroscopy of GABA: A methodological review. Prog Nucl Magn Reson Spectrosc. 2012;60:29–41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Roopun  AK, Middleton  SJ, Cunningham  MO, et al.  A beta2-frequency (20–30 Hz) oscillation in nonsynaptic networks of somatosensory cortex. Proc Natl Acad Sci U S A. 2006;103(42):15646–15650. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Yamawaki  N, Stanford  IM, Hall  SD, Woodhall  GL. Pharmacologically induced and stimulus evoked rhythmic neuronal oscillatory activity in the primary motor cortex in vitro. Neuroscience. 2008;151(2):386–395. [DOI] [PubMed] [Google Scholar]
  • 27. Hall  SD, Barnes  GR, Furlong  PL, Seri  S, Hillebrand  A. Neuronal network pharmacodynamics of GABAergic modulation in the human cortex determined using pharmaco-magnetoencephalography. Hum Brain Mapp. 2010;31(4):581–594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Jensen  O, Goel  P, Kopell  N, Pohja  M, Hari  R, Ermentrout  B. On the human sensorimotor-cortex beta rhythm: Sources and modeling. Neuroimage. 2005;26(2):347–355. [DOI] [PubMed] [Google Scholar]
  • 29. Muthukumaraswamy  SD, Edden  RA, Jones  DK, Swettenham  JB, Singh  KD. Resting GABA concentration predicts peak gamma frequency and fMRI amplitude in response to visual stimulation in humans. Proc Natl Acad Sci USA. 2009;106(20):8356–8361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Gaetz  W, Edgar  JC, Wang  DJ, Roberts  TP. Relating MEG measured motor cortical oscillations to resting γ-aminobutyric acid (GABA) concentration. Neuroimage. 2011;55(2):616–621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Kujala  J, Jung  J, Bouvard  S, et al.  Gamma oscillations in V1 are correlated with GABA(A) receptor density: A multi-modal MEG and flumazenil-PET study. Sci Rep. 2015;5:16347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Tokatly Latzer  I, Roullet  JB, Gibson  KM, Pearl  PL. Establishment and validation of a clinical severity scoring system for succinic semialdehyde dehydrogenase deficiency. J Inherit Metab Dis. 2023;46:992–1003. [DOI] [PubMed] [Google Scholar]
  • 33. Bowden  VR, Greenberg  CS. Pediatric nursing procedures (Bowden, pediatric nursing procedures). 3rd edn. Wolters Kluwer; 2016. [Google Scholar]
  • 34. Jansen  EE, Verhoeven  NM, Jakobs  C, et al.  Increased guanidino species in murine and human succinate semialdehyde dehydrogenase (SSADH) deficiency. Biochim Biophys Acta. 2006;1762(4):494–498. [DOI] [PubMed] [Google Scholar]
  • 35. Snyder  AZ, Raichle  ME. A brief history of the resting state: The Washington university perspective. Neuroimage. 2012;62:902–910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Rogala  J, Kublik  E, Krauz  R, Wróbel  A. Resting-state EEG activity predicts frontoparietal network reconfiguration and improved attentional performance. Sci Rep. 2020;10(1):5064. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Tadel  F, Baillet  S, Mosher  JC, Pantazis  D, Leahy  RM. Brainstorm: A user-friendly application for MEG/EEG analysis. Comput Intell Neurosci. 2011;2011:879716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Sanchez  CE, Richards  JE, Almli  CR. Age-specific MRI templates for pediatric neuroimaging. Dev Neuropsychol. 2012;37(5):379–399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Jung  TP, Makeig  S, Humphries  C, et al.  Removing electroencephalographic artifacts by blind source separation. Psychophysiology. 2000;37(2):163–178. [PubMed] [Google Scholar]
  • 40. Klados  MA, Papadelis  C, Braun  C, Bamidis  PD. REG-ICA: A hybrid methodology combining blind source separation and regression techniques for the rejection of ocular artifacts. Biomed Signal Process Control. 2011;6(3):291–300. [Google Scholar]
  • 41. Pascual-Marqui  RD, Esslen  M, Kochi  K, Lehmann  D. Functional mapping of electric neuronal activity with zero localization error: Standardized low-resolution brain electromagnetic tomography (sLORETA). In: 8th International Conference on Functional Mapping of the Human Brain, June 2–6, 2002, Sendai, Japan. Available on CD-Rom in NeuroImage, 2002, Vol. 16, No. 2.
  • 42. Fuchs  M, Wagner  M, Kastner  J. Boundary element method volume conductor models for EEG source reconstruction. Clin Neurophysiol. 2001;112(8):1400–1407. [DOI] [PubMed] [Google Scholar]
  • 43. Gramfort  A, Papadopoulo  T, Olivi  E, Clerc  M. OpenMEEG: Opensource software for quasistatic bioelectromagnetics. Biomed Eng Online. 2010;9:45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Pascual-Marqui  RD. Standardized low-resolution brain electromagnetic tomography (sLORETA): Technical details. Methods Find Exp Clin Pharmacol. 2002;24(Suppl D):5–12. [PubMed] [Google Scholar]
  • 45. Aranibar  A, Pfurtscheller  G. On and off effects in the background EEG activity during one-second photic stimulation. Electroencephalogr Clin Neurophysiol. 1978;44(3):307–316. [DOI] [PubMed] [Google Scholar]
  • 46. Afacan  O, Yang  E, Lin  AP, et al.  Magnetic resonance imaging (MRI) and spectroscopy in succinic semialdehyde dehydrogenase deficiency. J Child Neurol. 2021;36:1162–1168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Mescher  M, Merkle  H, Kirsch  J, Garwood  M, Gruetter  R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed. 1998;11(6):266–272. [DOI] [PubMed] [Google Scholar]
  • 48. Costigan  AG, Umla-Runge  K, Evans  CJ, Hodgetts  CJ, Lawrence  AD, Graham  KS. Neurochemical correlates of scene processing in the precuneus/posterior cingulate cortex: A multimodal fMRI and 1H-MRS study. Hum Brain Mapp. 2019;40:2884–2898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Duncan  NW, Zhang  J, Northoff  G, Weng  X. Investigating GABA concentrations measured with macromolecule suppressed and unsuppressed MEGA-PRESS MR spectroscopy and their relationship with BOLD responses in the occipital cortex. J Magn Reson Imaging. 2019;50:1285–1294. [DOI] [PubMed] [Google Scholar]
  • 50. Peek  AL, Rebbeck  TJ, Leaver  AM, et al.  A comprehensive guide to MEGA-PRESS for GABA measurement. Anal Biochem. 2023;15(669):115113. [DOI] [PubMed] [Google Scholar]
  • 51. Maris  E, Oostenveld  R. Nonparametric statistical testing of EEG- and MEG-data. J Neurosci Methods. 2007;164(1):177–190. [DOI] [PubMed] [Google Scholar]
  • 52. Ricci  L, Assenza  G, Pulitano  P, et al.  Measuring the effects of first antiepileptic medication in temporal lobe epilepsy: Predictive value of quantitative-EEG analysis. Clin Neurophysiol. 2021;132(1):25–35. [DOI] [PubMed] [Google Scholar]
  • 53. Lanzone  J, Boscarino  M, Ricci  L, et al.  The effects of antiepileptic drugs on high-frequency oscillations in somatosensory evoked potentials. Clin Neurophysiol. 2020;131(8):1917–1924. [DOI] [PubMed] [Google Scholar]
  • 54. Bak  LK, Schousboe  A, Waagepetersen  HS. The glutamate/GABA-glutamine cycle: Aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem. 2006;98(3):641–653. [DOI] [PubMed] [Google Scholar]
  • 55. Palma  E, Ruffolo  G, Cifelli  P, Roseti  C, Vliet  EAV, Aronica  E. Modulation of GABAA receptors in the treatment of epilepsy. Curr Pharm Des. 2017;23(37):5563–5568. [DOI] [PubMed] [Google Scholar]
  • 56. Banerjee  A, Rikhye  RV, Breton-Provencher  V, et al.  Jointly reduced inhibition and excitation underlies circuit-wide changes in cortical processing in Rett syndrome. Proc Natl Acad Sci U S A. 2016;113(46):E7287-E7296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Ruffolo  G, Iyer  A, Cifelli  P, et al.  Functional aspects of early brain development are preserved in tuberous sclerosis complex (TSC) epileptogenic lesions. Neurobiol Dis. 2016;95:93–101. [DOI] [PubMed] [Google Scholar]
  • 58. Cepeda  C, André  VM, Yamazaki  I, et al.  Comparative study of cellular and synaptic abnormalities in brain tissue samples from pediatric tuberous sclerosis complex and cortical dysplasia type II. Epilepsia. 2010;51(Suppl 3):160–165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Dan  B, Boyd  SG. Angelman syndrome reviewed from a neurophysiological perspective. The UBE3A-GABRB3 hypothesis. Neuropediatrics. 2003;34(4):169–176. [DOI] [PubMed] [Google Scholar]
  • 60. Deidda  G, Parrini  M, Naskar  S, Bozarth  IF, Contestabile  A, Cancedda  L. Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome. Nat Med. 2015;21(4):318–326. [DOI] [PubMed] [Google Scholar]
  • 61. Johnston  MV, Blue  ME, Naidu  S. Rett syndrome and neuronal development. J Child Neurol. 2005;20(9):759–763. [DOI] [PubMed] [Google Scholar]
  • 62. Talos  DM, Sun  H, Kosaras  B, et al.  Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia. Ann Neurol. 2012;71(4):539–551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63. Reis  J, Cohen  LG, Pearl  PL, et al.  GABAB-ergic motor cortex dysfunction in SSADH deficiency. Neurology. 2012;79(1):47–54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Latzer I  T, Bertoldi  M, DiBacco  ML, et al.  The presence and severity of epilepsy coincide with reduced γ-aminobutyrate and cortical excitatory markers in succinic semialdehyde dehydrogenase deficiency. Epilepsia. 2023;64:1516–1526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65. Tokatly Latzer  I, Hanson  E, Bertoldi  M, et al.  Autism spectrum disorder and GABA levels in children with succinic semialdehyde dehydrogenase deficiency. Dev Med Child Neurol. 2023. Advance Access published on May 28, 2023, doi: 10.1111/dmcn.15659. [DOI] [PubMed] [Google Scholar]
  • 66. Kirby  TO, Shi  X, Walters  D, Roullet  JB, Gibson  KM. Intestinal dysbiosis as a component of pathophysiology in succinic semialdehyde dehydrogenase deficiency (SSADHD). Mol Genet Metab. 2022;135(1):42–46. [DOI] [PubMed] [Google Scholar]
  • 67. Zhao  N, Shu  Y, Jian  C, et al.  Lactobacillus ameliorates SD-induced stress responses and gut dysbiosis by increasing the absorption of gut-derived GABA in rhesus monkeys. Front Immunol. 2022;13:915393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68. Cheron  G, Cebolla  AM, De Saedeleer  C, et al.  Pure phase-locking of beta/gamma oscillation contributes to the N30 frontal component of somatosensory evoked potentials. BMC Neurosci. 2007;8:75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69. Gross  J, Schnitzler  A, Timmermann  L, Ploner  M. Gamma oscillations in human primary somatosensory cortex reflect pain perception. PLoS Biol. 2007;5(5):e133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70. Fukuda  M, Nishida  M, Juhász  C, et al.  Short-latency median-nerve somatosensory-evoked potentials and induced gamma-oscillations in humans. Brain. 2008;131(Pt 7):1793–1805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71. Ross  B, Jamali  S, Miyazaki  T, Fujioka  T. Synchronization of β and γ oscillations in the somatosensory evoked neuromagnetic steady-state response. Exp Neurol. 2013;245:40–51. [DOI] [PubMed] [Google Scholar]
  • 72. Papadelis  C, Butler  EE, Rubenstein  M, et al.  Reorganization of the somatosensory cortex in hemiplegic cerebral palsy associated with impaired sensory tracts. Neuroimage Clin. 2017;17:198–212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73. Sanchez-Carpintero  R, Urrestarazu  E, Cieza  S, et al.  Abnormal brain gamma oscillations in response to auditory stimulation in Dravet syndrome. Eur J Paediatr Neurol. 2020;24:134–141. [DOI] [PubMed] [Google Scholar]
  • 74. An  KM, Ikeda  T, Yoshimura  Y, et al.  Altered gamma oscillations during motor control in children with autism spectrum disorder. J Neurosci. 2018;38(36):7878–7886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75. Fitzgerald  PJ, Watson  BO. Gamma oscillations as a biomarker for major depression: An emerging topic. Transl Psychiatry. 2018;8(1):177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76. Mably  AJ, Colgin  LL. Gamma oscillations in cognitive disorders. Curr Opin Neurobiol. 2018;52:182–187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77. Herrmann  CS, Demiralp  T. Human EEG gamma oscillations in neuropsychiatric disorders. Clin Neurophysiol. 2005;116(12):2719–2733. [DOI] [PubMed] [Google Scholar]
  • 78. Artieda  J, Valencia  M, Alegre  M, Olaziregi  O, Urrestarazu  E, Iriarte  J. Potentials evoked by chirp-modulated tones: A new technique to evaluate oscillatory activity in the auditory pathway. Clin Neurophysiol. 2004;115(3):699–709. [DOI] [PubMed] [Google Scholar]
  • 79. Muthukumaraswamy  SD, Myers  JF, Wilson  SJ, et al.  Elevating endogenous GABA levels with GAT-1 blockade modulates evoked but not induced responses in human visual cortex. Neuropsychopharmacology. 2013;38(6):1105–1112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80. Brunel  N, Wang  XJ. Effects of neuromodulation in a cortical network model of object working memory dominated by recurrent inhibition. J Comput Neurosci. 2001;11(1):63–85. [DOI] [PubMed] [Google Scholar]
  • 81. Meador  KJ, Ray  PG, Echauz  JR, Loring  DW, Vachtsevanos  GJ. Gamma coherence and conscious perception. Neurology. 2002;59:847–854. [DOI] [PubMed] [Google Scholar]
  • 82. Womelsdorf  T, Fries  P, Mitra  PP, Desimone  R. Gamma-band synchronization in visual cortex predicts speed of change detection. Nature. 2006;439(7077):733–736. [DOI] [PubMed] [Google Scholar]
  • 83. Eccles  JC. The inhibitory pathways of the central nervous system (Sherrington lecture). University Press; 1969. [Google Scholar]
  • 84. Yoon  JH, Maddock  RJ, Rokem  A, et al.  GABA Concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. J Neurosci. 2010;30(10):3777–3781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85. Rowland  LM, Edden  RA, Kontson  K, Zhu  H, Barker  PB, Hong  LE. GABA predicts inhibition of frequency-specific oscillations in schizophrenia. J Neuropsychiatry Clin Neurosci. 2013;25(1):83–87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86. Di Lazzaro  V, Pilato  F, Saturno  E, et al.  Theta-burst repetitive transcranial magnetic stimulation suppresses specific excitatory circuits in the human motor cortex. J Physiol. 2005;565(Pt 3):945–950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87. Bartos  M, Vida  I, Jonas  P. Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nat Rev Neurosci. 2007;8(1):45–56. [DOI] [PubMed] [Google Scholar]
  • 88. Traub  RD, Whittington  MA, Colling  SB, Buzsáki  G, Jefferys  JG. Analysis of gamma rhythms in the rat hippocampus in vitro and in vivo. J Physiol. 1996;493(Pt 2):471–484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89. Dalby  NO. GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors. Neuropharmacology. 2000;39(12):2399–2407. [DOI] [PubMed] [Google Scholar]
  • 90. Fink-Jensen  A, Suzdak  PD, Swedberg  MD, Judge  ME, Hansen  L, Nielsen  PG. The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol. 1992;220(2–3):197–201. [DOI] [PubMed] [Google Scholar]
  • 91. Webster  K, Ro  T. Visual modulation of resting state α oscillations. eNeuro. 2020;7(1):ENEURO.0268-19.2019. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

fcad291_Supplementary_Data

Data Availability Statement

Anonymized data are available from the corresponding author upon request.


Articles from Brain Communications are provided here courtesy of Oxford University Press

RESOURCES